219 related articles for article (PubMed ID: 29034540)
1. Ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by inhibition of drug resistance.
Zhang Y; Huang L; Shi H; Chen H; Tao J; Shen R; Wang T
Cancer Sci; 2018 Jan; 109(1):94-102. PubMed ID: 29034540
[TBL] [Abstract][Full Text] [Related]
2. Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer.
Shan J; Xuan Y; Zhang Q; Zhu C; Liu Z; Zhang S
Protein Cell; 2016 Aug; 7(8):571-85. PubMed ID: 27472952
[TBL] [Abstract][Full Text] [Related]
3. Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine.
Prasad S; Yadav VR; Sung B; Reuter S; Kannappan R; Deorukhkar A; Diagaradjane P; Wei C; Baladandayuthapani V; Krishnan S; Guha S; Aggarwal BB
Clin Cancer Res; 2012 Sep; 18(18):4942-53. PubMed ID: 22832932
[TBL] [Abstract][Full Text] [Related]
4. Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.
Gaur S; Chen L; Ann V; Lin WC; Wang Y; Chang VH; Hsu NY; Shia HS; Yen Y
Mol Cancer; 2014 Feb; 13():21. PubMed ID: 24495750
[TBL] [Abstract][Full Text] [Related]
5. Ursolic acid potentiated oxaliplatin to induce apoptosis in colorectal cancer RKO cells.
Zheng J-; Wang SS; Shen KP; Huang XW; Li M; Chen L; Peng X; An HM; Hu B
Pharmazie; 2020 Jun; 75(6):246-249. PubMed ID: 32539919
[TBL] [Abstract][Full Text] [Related]
6. The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress.
Chen W; Lian W; Yuan Y; Li M
Cell Death Dis; 2019 Aug; 10(8):600. PubMed ID: 31395855
[TBL] [Abstract][Full Text] [Related]
7. Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer.
Kim BR; Jeong YA; Jo MJ; Park SH; Na YJ; Kim JL; Jeong S; Yun HK; Kang S; Lee DH; Oh SC
Mol Cancer Ther; 2019 Apr; 18(4):751-761. PubMed ID: 30787174
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis.
Lu YX; Ju HQ; Wang F; Chen LZ; Wu QN; Sheng H; Mo HY; Pan ZZ; Xie D; Kang TB; Chen G; Yun JP; Zeng ZL; Xu RH
Cancer Lett; 2016 Sep; 380(1):87-97. PubMed ID: 27322737
[TBL] [Abstract][Full Text] [Related]
9. Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer.
Santoro V; Jia R; Thompson H; Nijhuis A; Jeffery R; Kiakos K; Silver AR; Hartley JA; Hochhauser D
J Natl Cancer Inst; 2016 Jun; 108(6):djv394. PubMed ID: 26719345
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.
Lu WQ; Hu YY; Lin XP; Fan W
Oncotarget; 2017 Jul; 8(27):44171-44185. PubMed ID: 28498807
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells.
Fiore D; Proto MC; Pisanti S; Picardi P; Pagano Zottola AC; Butini S; Gemma S; Casagni A; Laezza C; Vitale M; Ligresti A; Di Marzo V; Zisterer DM; Nathwani S; Williams DC; Campiani G; Gazzerro P; Bifulco M
Cancer Biol Ther; 2016 Aug; 17(8):849-58. PubMed ID: 26392056
[TBL] [Abstract][Full Text] [Related]
12. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
Chian S; Li YY; Wang XJ; Tang XW
Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.
Perez M; Lucena-Cacace A; Marín-Gómez LM; Padillo-Ruiz J; Robles-Frias MJ; Saez C; Garcia-Carbonero R; Carnero A
Oncotarget; 2016 May; 7(22):33111-24. PubMed ID: 27105527
[TBL] [Abstract][Full Text] [Related]
15. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
[TBL] [Abstract][Full Text] [Related]
16. Disrupting G6PD-mediated Redox homeostasis enhances chemosensitivity in colorectal cancer.
Ju HQ; Lu YX; Wu QN; Liu J; Zeng ZL; Mo HY; Chen Y; Tian T; Wang Y; Kang TB; Xie D; Zeng MS; Huang P; Xu RH
Oncogene; 2017 Nov; 36(45):6282-6292. PubMed ID: 28692052
[TBL] [Abstract][Full Text] [Related]
17. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
[TBL] [Abstract][Full Text] [Related]
18. Ursolic acid sensitized colon cancer cells to chemotherapy under hypoxia by inhibiting MDR1 through HIF-1α.
Shan JZ; Xuan YY; Zhang Q; Huang JJ
J Zhejiang Univ Sci B; 2016 Sep; 17(9):672-82. PubMed ID: 27604859
[TBL] [Abstract][Full Text] [Related]
19. HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy.
Nagaraju GP; Alese OB; Landry J; Diaz R; El-Rayes BF
Oncotarget; 2014 Oct; 5(20):9980-91. PubMed ID: 25296971
[TBL] [Abstract][Full Text] [Related]
20. Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer.
Dong Y; Wang Z; Xie GF; Li C; Zuo WW; Meng G; Xu CP; Li JJ
Mol Cancer; 2017 Mar; 16(1):71. PubMed ID: 28356150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
